Browse drugs

…elial growth factor (anti-VEGF) agents, such as aflibercept and ranibizumab, are widely used. Although generally safe, they carry a risk of…

…tients (10 injections); faricimab 94 patients (321 injections); ranibizumab 37 patients (127 injections).Classified by most frequent diagno…

…: 1.42; 95% CI: 1.24 to 1.63), compared with those treated with ranibizumab, and specifically also a higher risk of acute kidney injury (HR…

…and DME are leading causes of vision loss, with ranibizumab and aflibercept as key treatments. However, frequent monthly injections create …

…herapy for geographic atrophy, administered in combination with ranibizumab, an approved therapy for neovascular age-related macular degene…

…subfield thickness (CST) (390.13 µm vs 334.20 µm, p=0.033) than aflibercept patients. Baseline HbA1c (p=0.012) and number of bevacizumab in…

…m baseline was +16.52 letters for 601 versus +17.79 letters for ranibizumab (adjusted mean difference: −1.27 letters (95% CI −5.439 to 2.89…

…naïve patients experienced modest improvement in visual acuity. Aflibercept enabled extended injection intervals in both groups, particular…

… (95% CI) difference of −6.53 (−12.47 to −0.58 µm) in favour of ranibizumab (23.53 (18.58 to 28.49) µm) versus aflibercept (30.06 (25.04 to…

…otal of 3,223 patients received 31,826 intravitreal injections. Bevacizumab was the most frequently prescribed drug (58.73%, n=18,690), fol…

…III randomised controlled trials (RCTs) evaluating ranibizumab, brolucizumab, aflibercept, and faricimab in nAMD. Baseline characteristics i…

…blinded, controlled pilot study CARE-ROP (Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity).…